Capricor Therapeutics Inc. (CAPR)
What Makes Capricor (CAPR) a Good Fit for 'Trend Investing'
If you are looking for stocks that are well positioned to maintain their recent uptrend, Capricor (CAPR) could be a great choice. It is one of the several stocks that passed through our "Recent Price Strength" screen.
Does Capricor (CAPR) Have the Potential to Rally 90.16% as Wall Street Analysts Expect?
The mean of analysts' price targets for Capricor (CAPR) points to a 90.2% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Capricor Therapeutics Is Up Over 100%, Could Rise Even Higher
Capricor Therapeutics Inc. CAPR is a biotechnology firm focused on developing cell and exosome-based treatments for rare diseases like Duchenne muscular dystrophy (DMD). Capricor's stock surged more than 100% after announcing it will pursue full FDA approval for its primary drug deramiocel (CAP-1002) in this year.
Capricor Therapeutics is up over 100%, Could Rise Even Higher
Capricor Therapeutics Inc. NASDAQ: CAPR is a biotechnology firm focused on developing cell and exosome-based treatments for rare diseases like Duchenne muscular dystrophy (DMD). Capricor's stock surged more than 100% after announcing it will pursue full FDA approval for its primary drug deramiocel (CAP-1002) in this year.
Check Out Last Week's Big Insider Buying: Biotechs, Energy, and More
24/7 Wall St. Insights Summer gave way to autumn this past week, and notable insider buying continued.
Capricor: DMD Treatment Focus With Deramiocel Is Likely To Pay Off
BLA submission of deramiocel for treatment of patients with DMD cardiomyopathy is expected in October 2024, with the completed portion expected before the end of 2024. The Duchenne Muscular Dystrophy drugs market size is projected to reach $5.5 billion by 2032. There is potential to eventually expand the label of deramiocel with positive results from Cohort A and Cohort B of the Phase 3 HOPE-3 study to target DMD skeletal muscle myopathy patients.
Capricor (CAPR) Surges 18.2%: Is This an Indication of Further Gains?
Capricor (CAPR) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
Capricor Therapeutics, Inc. (CAPR) Q2 2024 Earnings Call Transcript
Capricor Therapeutics, Inc. (NASDAQ:CAPR ) Q2 2024 Earnings Conference Call August 7, 2024 4:30 PM ET Company Participants Linda Marban – Chief Executive Officer AJ Bergmann – Chief Financial Officer Conference Call Participants Joseph Pantginis – H.C. Wainwright Leland Gershell – Oppenheimer Aydin Huseynov – Ladenburg Rick Miller – Cantor Operator Good afternoon, ladies and gentlemen, and welcome to the Capricor Therapeutics Second Quarter 2024 Earnings Call.
Capricor Therapeutics (CAPR) Reports Q2 Loss, Misses Revenue Estimates
Capricor Therapeutics (CAPR) came out with a quarterly loss of $0.35 per share versus the Zacks Consensus Estimate of a loss of $0.32. This compares to loss of $0.29 per share a year ago.
Capricor (CAPR) Advances in DMD Therapy With Positive Study Data
Capricor (CAPR) anticipates announcing top-line results from the Phase 3 HOPE-3 pivotal trial by the fourth quarter of 2024.
